Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Fondaparinux vs. enoxaparin in patients with non-ST elevation acute coronary syndromes (NSTE-ACS) treated with percutaneous coronary intervention and tirofiban: an exploratory study in China.

Tytuł :
Fondaparinux vs. enoxaparin in patients with non-ST elevation acute coronary syndromes (NSTE-ACS) treated with percutaneous coronary intervention and tirofiban: an exploratory study in China.
Autorzy :
Zhao XM; Department of Emergency, Henan Provincial People's Hospital and the People's Hospital of Zhengzhou University, Zhengzhou, China.
Gao CY; Department of Cardiology, Henan Provincial People's Hospital and the People's Hospital of Zhengzhou University, Zhengzhou, China.
Chu YJ; Department of Emergency, Henan Provincial People's Hospital and the People's Hospital of Zhengzhou University, Zhengzhou, China.
Yang L; Department of Emergency, Henan Provincial People's Hospital and the People's Hospital of Zhengzhou University, Zhengzhou, China.
Yang XZ; Department of Emergency, Henan Provincial People's Hospital and the People's Hospital of Zhengzhou University, Zhengzhou, China.
Xu WK; Department of Emergency, Henan Provincial People's Hospital and the People's Hospital of Zhengzhou University, Zhengzhou, China.
He WQ; Department of Emergency, Henan Provincial People's Hospital and the People's Hospital of Zhengzhou University, Zhengzhou, China.
Zhang PR; Department of Emergency, Henan Provincial People's Hospital and the People's Hospital of Zhengzhou University, Zhengzhou, China.
Liu XY; Department of Emergency, Henan Provincial People's Hospital and the People's Hospital of Zhengzhou University, Zhengzhou, China.
Tian LX; Department of Emergency, Henan Provincial People's Hospital and the People's Hospital of Zhengzhou University, Zhengzhou, China.
Pokaż więcej
Źródło :
Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2015 Oct; Vol. 40 (5), pp. 584-589. Date of Electronic Publication: 2015 Aug 06.
Typ publikacji :
Journal Article
Język :
English
Imprint Name(s) :
Publication: Oxford : Wiley-Blackwell Pub.
Original Publication: Oxford : Blackwell Scientific Publications, c1987-
Contributed Indexing :
Keywords: acute coronary syndrome; efficacy; enoxaparin; fondaparinux; safety; tirofiban
Entry Date(s) :
Date Created: 20150808 Latest Revision: 20191120
Update Code :
20201019
DOI :
10.1111/jcpt.12315
PMID :
26249542
Czasopismo naukowe
What Is Known and Objective: Fondaparinux and enoxaparin are used in patients with acute coronary syndrome (ACS), but their effect in particular populations of patients is not well known. The objective was to explore the difference between fondaparinux and enoxaparin in patients with non-ST elevation ACS (NSTE-ACS) treated with percutaneous coronary intervention (PCI) and tirofiban.
Methods: We prospectively enrolled 461 patients with NSTE-ACS treated with PCI, tirofiban, and either fondaparinux (n = 229) or enoxaparin (n = 232). Death, myocardial infarction, recurrent ischaemia and its composite outcome were assessed. The incidences of major or minor bleeding not related to coronary artery bypass grafting were also evaluated.
Results and Discussion: The rates of death, MI or refractory angina did not differ between the fondaparinux and enoxaparin groups at day 7 (4·40% vs. 4·70%), 30 (7·90% vs. 8·60%) or 180 (9·60% vs. 10·80%). Similarly, there were not statistically significant differences in the rates of major bleeding at day 7 (0·87% vs. 2·16%), 30 (1·31% vs. 2·59%) or 180 (2·18% vs. 3·88%), or in the rates of minor bleeding at day 7 (3·49% vs. 6·47%), 30 (5·68% vs. 9·48%) or 180 (8·30% vs. 13·36%).
What Is New and Conclusion: In this relatively small study of Chinese patients with NSTE-ACS treated with tirofiban, there was no statistically significant difference in ischaemic or bleeding outcomes with the use of either fondaparinux or enoxaparin.
(© 2015 John Wiley & Sons Ltd.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies